Compounds with a BENZENE fused to IMIDAZOLES.
DrugDrug NameDrug Indication
DB00213Pantoprazole **Pantoprazole Injection**: **Treatment of gastroesophageal reflux disease associated with a history of erosive esophagitis** Pantoprazole for injection is indicated for short-term treatment (7-10 days) of patients having gastroesophageal reflux disease (GERD) with a history of erosive esophagitis, as an alternative to oral medication in patients who are unable to continue taking pantoprazole delayed-release tablets. _Safety and efficacy of pantoprazole injection as the initial treatment of patients having GERD with a history of erosive esophagitis have not been demonstrated at this time_.[FDA label] **Pathological Hypersecretion Associated with Zollinger-Ellison Syndrome** Pantoprazole for injection is indicated for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions.[FDA label] **Pantoprazole delayed-release oral suspension**: **Short-Term Treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD)** Indicated in adults and pediatric patients five years of age and above for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For adult patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been determined.[F3202] **Maintenance of healing of erosive esophagitis** Indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD.[F3202] **Pathological hypersecretory conditions including Zollinger-Ellison syndrome** Indicated for the long-term treatment of the above conditions.[F3202]
DB00338OmeprazoleOmeprazole, according to the FDA label [FDA label] is a proton pump inhibitor (PPI) used for the following purposes: • Treatment of active duodenal ulcer in adults • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults • Treatment of active benign gastric ulcer in adults • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older • Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older • Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older • Pathologic hypersecretory conditions in adults
DB00448LansoprazoleLansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. [A4892][A177065][FDA Label] It may be used in the maintenance and healing of several gastric conditions including duodenal ulcers, NSAID related gastric ulcers, and erosive esophagitis.[FDA Label] Lansoprazole prevents recurrence of gastric ulcers in patients who have a documented history of gastric ulcers who also use NSAIDs chronically. [FDA Label] Predictably, it is also useful in the management of hypersecretory conditions including Zollinger-Ellison syndrome. [FDA Label] Lansoprazole is effective at eradicating H. pylori when used in conjunction with amoxicillin and clarithromycin (triple therapy) or with amoxicillin alone (dual therapy). [FDA Label]
DB00450DroperidolDroperidol is ssed to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
DB00518AlbendazoleFor the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium and for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.
DB00637AstemizoleAstemizole was indicated for use in the relieving allergy symptoms, particularly rhinitis and conjunctivitis. It has been withdrawn from the market however due to concerns of arrhythmias.
DB00643MebendazoleFor the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections.
DB00730ThiabendazoleFor the treatment of strongyloidiasis (threadworm), cutaneous larva migrans (creeping eruption), visceral larva migrans, and trichinosis.
DB00736EsomeprazoleEsomeprazole is indicated for the treatment of acid-reflux disorders including healing and maintenance of erosive esophagitis, and symptomatic gastroesophageal reflux disease (GERD), peptic ulcer disease, H. pylori eradication, prevention of gastrointestinal bleeds with NSAID use, and for the long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison Syndrome.
DB01100PimozideUsed for the suppression of motor and phonic tics in patients with Tourette's Disorder who have failed to respond satisfactorily to standard treatment.
DB01129RabeprazoleFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
DB01184DomperidoneFor management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.
DB01388MibefradilFor the treatment of angina and high blood pressure.
DB05351DexlansoprazoleDexlansoprazole is indicated for healing all grades of erosive esophagitis (EE), maintaining and healing of EE and relief of heartburn, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).
DB06695Dabigatran etexilateDabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials)[A177463,A6978,A6977]. In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial)[Label,A177463].
DB06769BendamustineBendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
DB08313nocodazoleNot Available
DB08974FlubendazoleNot Available
DB11380CambendazoleNot Available
DB11410FenbendazoleNot Available
DB11446OxfendazoleNot Available
DB11964IlaprazoleNot Available
DB13135AGN-201904Not Available
DB13762DexrabeprazoleNot Available
DB13871Albendazole oxideNot Available
DB14726DabigatranNot Available
DrugDrug NameTargetType
DB00213PantoprazolePotassium-transporting ATPase alpha chain 1target
DB00213PantoprazoleCytochrome P450 2C19enzyme
DB00213PantoprazoleCytochrome P450 3A4enzyme
DB00213PantoprazoleMultidrug resistance protein 1transporter
DB00213PantoprazoleATP-binding cassette sub-family G member 2transporter
DB00213PantoprazoleSolute carrier family 22 member 8transporter
DB00213PantoprazoleN(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
DB00338OmeprazolePotassium-transporting ATPase alpha chain 1target
DB00338OmeprazoleCytochrome P450 2C19enzyme
DB00338OmeprazoleCytochrome P450 3A4enzyme
DB00338OmeprazoleCytochrome P450 2C9enzyme
DB00338OmeprazoleCytochrome P450 1A2enzyme
DB00338OmeprazoleCanalicular multispecific organic anion transporter 2transporter
DB00338OmeprazoleMultidrug resistance protein 1transporter
DB00338OmeprazoleATP-binding cassette sub-family G member 2transporter
DB00338OmeprazoleCytochrome P450 1A1enzyme
DB00338OmeprazoleCytochrome P450 1B1enzyme
DB00338OmeprazoleCytochrome P450 2C18enzyme
DB00338OmeprazoleCytochrome P450 2C8enzyme
DB00338OmeprazoleCytochrome P450 2D6enzyme
DB00338OmeprazoleAryl hydrocarbon receptortarget
DB00448LansoprazolePotassium-transporting ATPase alpha chain 1target
DB00448LansoprazoleCytochrome P450 2C19enzyme
DB00448LansoprazoleCytochrome P450 2C9enzyme
DB00448LansoprazoleCytochrome P450 3A4enzyme
DB00448LansoprazoleMultidrug resistance protein 1transporter
DB00448LansoprazoleATP-binding cassette sub-family G member 2transporter
DB00448LansoprazoleCytochrome P450 1A1enzyme
DB00448LansoprazoleCytochrome P450 1B1enzyme
DB00448LansoprazoleCytochrome P450 2C18enzyme
DB00448LansoprazoleCytochrome P450 2C8enzyme
DB00448LansoprazoleCytochrome P450 2D6enzyme
DB00448LansoprazoleMicrotubule-associated protein tautarget
DB00448LansoprazoleSolute carrier family 22 member 8transporter
DB00448LansoprazoleSolute carrier family 22 member 1transporter
DB00448LansoprazoleSolute carrier family 22 member 2transporter
DB00448LansoprazoleSolute carrier family 22 member 3transporter
DB00450DroperidolD(2) dopamine receptortarget
DB00450DroperidolAlpha-1A adrenergic receptortarget
DB00518AlbendazoleTubulin alpha-1A chaintarget
DB00518AlbendazoleTubulin beta-4B chaintarget
DB00518AlbendazoleCytochrome P450 3A4enzyme
DB00518AlbendazoleFumarate reductase flavoprotein subunittarget
DB00518AlbendazoleMultidrug resistance protein 1transporter
DB00518AlbendazoleCytochrome P450 1A1enzyme
DB00518AlbendazoleCytochrome P450 1A2enzyme
DB00518AlbendazoleTubulin beta-2 chaintarget
DB00518AlbendazoleCytochrome P450 2C19enzyme
DB00637AstemizoleHistamine H1 receptortarget
DB00637AstemizolePotassium voltage-gated channel subfamily H member 2target
DB00637AstemizoleCytochrome P450 3A4enzyme
DB00637AstemizoleCytochrome P450 3A5enzyme
DB00637AstemizoleCytochrome P450 3A7enzyme
DB00637AstemizoleMultidrug resistance protein 1transporter
DB00637AstemizoleCytochrome P450 2D6enzyme
DB00637AstemizoleCytochrome P450 2J2enzyme
DB00637AstemizolePotassium voltage-gated channel subfamily H member 1target
DB00637AstemizoleMicrotubule-associated protein tautarget
DB00637AstemizoleBile salt export pumptransporter
DB00643MebendazoleTubulin alpha-1A chaintarget
DB00643MebendazoleTubulin beta-4B chaintarget
DB00643MebendazoleCytochrome P450 3A4enzyme
DB00643MebendazoleCytochrome P450 1A1enzyme
DB00730ThiabendazoleFumarate reductase flavoprotein subunittarget
DB00730ThiabendazoleCytochrome P450 1A2enzyme
DB00730ThiabendazoleCytochrome P450 1A1enzyme
DB00736EsomeprazolePotassium-transporting ATPase alpha chain 1target
DB00736EsomeprazoleCytochrome P450 2C19enzyme
DB00736EsomeprazoleCytochrome P450 3A4enzyme
DB00736EsomeprazoleN(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
DB00736EsomeprazoleMultidrug resistance protein 1transporter
DB00736EsomeprazoleSolute carrier family 22 member 8transporter
DB01100PimozideD(2) dopamine receptortarget
DB01100PimozidePotassium voltage-gated channel subfamily H member 2target
DB01100PimozideCytochrome P450 3A4enzyme
DB01100PimozideCytochrome P450 1A2enzyme
DB01100PimozideCytochrome P450 3A5enzyme
DB01100PimozideCytochrome P450 3A7enzyme
DB01100PimozideMultidrug resistance protein 1transporter
DB01100PimozideD(3) dopamine receptortarget
DB01100PimozideCytochrome P450 2D6enzyme
DB01100PimozideCytochrome P450 2E1enzyme
DB01129RabeprazolePotassium-transporting ATPase alpha chain 1target
DB01129RabeprazoleCytochrome P450 3A4enzyme
DB01129RabeprazoleCytochrome P450 2C19enzyme
DB01129RabeprazoleATP-binding cassette sub-family G member 2transporter
DB01129RabeprazoleCytochrome P450 1A1enzyme
DB01129RabeprazoleCytochrome P450 1A2enzyme
DB01129RabeprazoleCytochrome P450 2C9enzyme
DB01129RabeprazoleCytochrome P450 2D6enzyme
DB01129RabeprazoleCytochrome P450 2C8enzyme
DB01184DomperidoneD(2) dopamine receptortarget
DB01184DomperidoneCytochrome P450 3A4enzyme
DB01184DomperidoneCytochrome P450 3A5enzyme
DB01184DomperidoneCytochrome P450 3A7enzyme
DB01184DomperidoneMultidrug resistance protein 1transporter
DB01184DomperidoneCytochrome P450 1A2enzyme
DB01184DomperidoneCytochrome P450 2B6enzyme
DB01184DomperidoneCytochrome P450 2C8enzyme
DB01184DomperidoneCytochrome P450 2D6enzyme
DB01184DomperidoneD(3) dopamine receptortarget
DB01388MibefradilVoltage-dependent T-type calcium channel subunit alpha-1Gtarget
DB01388MibefradilVoltage-dependent T-type calcium channel subunit alpha-1Htarget
DB01388MibefradilVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB01388MibefradilVoltage-dependent L-type calcium channel subunit beta-1target
DB01388MibefradilCytochrome P450 3A4enzyme
DB01388MibefradilCytochrome P450 1A2enzyme
DB01388MibefradilCytochrome P450 2D6enzyme
DB01388MibefradilCytochrome P450 3A5enzyme
DB01388MibefradilCytochrome P450 3A7enzyme
DB01388MibefradilMultidrug resistance protein 1transporter
DB01388MibefradilVoltage-dependent T-type calcium channel subunit alpha-1Itarget
DB01388MibefradilVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB01388MibefradilVoltage-dependent L-type calcium channel subunit alpha-1Ftarget
DB01388MibefradilVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB01388MibefradilVoltage-dependent L-type calcium channel subunit beta-2target
DB01388MibefradilVoltage-dependent L-type calcium channel subunit beta-3target
DB01388MibefradilVoltage-dependent L-type calcium channel subunit beta-4target
DB01388MibefradilCytochrome P450 11B1, mitochondrialenzyme
DB01388MibefradilCytochrome P450 11B2, mitochondrialenzyme
DB01388MibefradilCytochrome P450 1A1enzyme
DB05351DexlansoprazolePotassium-transporting ATPase alpha chain 1target
DB05351DexlansoprazoleCytochrome P450 2C19enzyme
DB05351DexlansoprazoleCytochrome P450 3A4enzyme
DB05351DexlansoprazolePotassium-transporting ATPase subunit betatarget
DB05351DexlansoprazoleN(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
DB06695Dabigatran etexilateProthrombintarget
DB06695Dabigatran etexilateMultidrug resistance protein 1transporter
DB06695Dabigatran etexilateLiver carboxylesterase 1enzyme
DB06695Dabigatran etexilateCocaine esteraseenzyme
DB06695Dabigatran etexilateUDP-glucuronosyltransferase 1-9enzyme
DB06695Dabigatran etexilateUDP-glucuronosyltransferase 2B7enzyme
DB06695Dabigatran etexilateUDP-glucuronosyltransferase 2B15enzyme
DB06695Dabigatran etexilateRibosyldihydronicotinamide dehydrogenase [quinone]enzyme
DB06769BendamustineCytochrome P450 1A2enzyme
DB08313nocodazoleHematopoietic prostaglandin D synthasetarget
DB13762DexrabeprazoleCytochrome P450 2C19enzyme